| Literature DB >> 30154149 |
Noémie Braekeveldt1, Kristoffer von Stedingk2,3, Susanne Fransson4, Angela Martinez-Monleon4, David Lindgren1, Håkan Axelson1, Fredrik Levander5, Jakob Willforss5, Karin Hansson5, Ingrid Øra6, Torbjörn Backman7, Anna Börjesson7, Siv Beckman1, Javanshir Esfandyari1, Ana P Berbegall8, Rosa Noguera8, Jenny Karlsson9, Jan Koster3, Tommy Martinsson4, David Gisselsson9,10, Sven Påhlman1, Daniel Bexell11,10.
Abstract
Patient-derived xenografts (PDX) and the Avatar, a single PDX mirroring an individual patient, are emerging tools in preclinical cancer research. However, the consequences of intratumor heterogeneity for PDX modeling of biomarkers, target identification, and treatment decisions remain underexplored. In this study, we undertook serial passaging and comprehensive molecular analysis of neuroblastoma orthotopic PDXs, which revealed strong intrinsic genetic, transcriptional, and phenotypic stability for more than 2 years. The PDXs showed preserved neuroblastoma-associated gene signatures that correlated with poor clinical outcome in a large cohort of patients with neuroblastoma. Furthermore, we captured spatial intratumor heterogeneity using ten PDXs from a single high-risk patient tumor. We observed diverse growth rates, transcriptional, proteomic, and phosphoproteomic profiles. PDX-derived transcriptional profiles were associated with diverse clinical characteristics in patients with high-risk neuroblastoma. These data suggest that high-risk neuroblastoma contains elements of both temporal stability and spatial intratumor heterogeneity, the latter of which complicates clinical translation of personalized PDX-Avatar studies into preclinical cancer research.Significance: These findings underpin the complexity of PDX modeling as a means to advance translational applications against neuroblastoma. Cancer Res; 78(20); 5958-69. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30154149 DOI: 10.1158/0008-5472.CAN-18-0527
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701